Key Pharmacologic Principles and Drug-Drug Interactions in HIV Patient Care
Summary
- Multiple interactions have been described between HCV DAAs and antiretrovirals (Table 12); thus, the concomitant treatment of both HCV and HIV must be planned carefully with consideration of these interactions
- Management guidelines provide specific guidance on the use of HCV DAAs with ARV agents[DHHS ART; AASLD/IDSA HCV]
- HCV DAAs also have multiple important interactions with other agents that are commonly used by HIV-infected patients; prescribing information should be checked carefully before initiating either agent[DHHS ART; FDA Simeprevir; FDA Ledipasvir/Sofosbuvir; FDA Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir; FDA Sofosbuvir/Velpatasvir; FDA Elbasvir/Grazoprevir; FDA Daclatasvir; FDA Sofosbuvir; FDA Glecaprevir/Pibrentasvir; FDA Sofosbuvir/Velpatasvir/Voxilaprevir; AASLD/IDSA HCV]
Action required
- Login now to access all of your entitled content
or - View additional options to gain access to this content
Keywords: Drug-Drug Interactions, Pharmacokinetics